Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Allogene Therapeutics, Inc. ALLO
$6.10
-$0.08 (-1.29%)
На 18:01, 12 мая 2023
+461.48%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
913700130.00000000
-
week52high
17.49
-
week52low
4.42
-
Revenue
243000
-
P/E TTM
-2740
-
Beta
0.76325200
-
EPS
-2.24000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 21:00
Описание компании
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 10 авг 2022 г. |
| Raymond James | Market Perform | Outperform | 10 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 10 авг 2022 г. |
| Goldman Sachs | Buy | Neutral | 15 июл 2022 г. |
| Baird | Neutral | 03 июн 2022 г. | |
| B. Riley Securities | Buy | Buy | 22 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 ноя 2022 г. |
| Baird | Outperform | Neutral | 06 янв 2023 г. |
| EF Hutton | Buy | 05 янв 2023 г. | |
| B of A Securities | Underperform | Buy | 12 дек 2022 г. |
| JP Morgan | Overweight | Neutral | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Roberts Zachary | A | 873015 | 873015 | 20 янв 2023 г. |
| Roberts Zachary | A | 251908 | 251908 | 20 янв 2023 г. |
| Bhavnagri Veer | D | 580677 | 3000 | 17 янв 2023 г. |
| Bhavnagri Veer | D | 583677 | 5602 | 15 дек 2022 г. |
| Amado Rafael | D | 541946 | 8464 | 07 окт 2022 г. |
| Amado Rafael | A | 550410 | 19120 | 07 окт 2022 г. |
| Amado Rafael | D | 531290 | 8968 | 03 окт 2022 г. |
| WITTE OWEN N. | D | 218271 | 5000 | 12 авг 2022 г. |
| WITTE OWEN N. | D | 223271 | 10000 | 11 авг 2022 г. |
| Amado Rafael | D | 540257 | 2000 | 02 авг 2022 г. |
Новостная лента
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
05 мая 2023 г. в 11:23
Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
Zacks Investment Research
04 мая 2023 г. в 13:41
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.
Allogene Therapeutics, Inc. (ALLO) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 23:49
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer Dr. David Chang - President and CEO Dr. Zachary Roberts - Executive Vice President, Research and Development and CMO Dr. Eric Schmidt - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Matt Borsch - Goldman Sachs Michael Yee - Jefferies Mark Breidenbach - OpCo Jack Allen - Baird Brian Cheng - JPMorgan John Newman - Canaccord Genuity Kalpit Patel - B. Riley Asthika Goonewardene - Truist Reni Benjamin - JMP Securities Jason Gerberry - Bank of America Securities William Pickering - Bernstein Luca Issi - RBC Capital Sami Corwin - William Blair Ben Burnett - Stifel Operator Hello and thank you for standing by.
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 19:02
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.56 per share a year ago.
Should You Buy Allogene Therapeutics (ALLO) Ahead of Earnings?
Zacks Investment Research
02 мая 2023 г. в 12:57
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.